drugset
Drugs / MBM-01
last change Dec 2022 re-read 3 minutes ago

MBM-01

also known as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl
Developed for
ataxia telangiectasia
Investigated by
Matrix Biomed, Inc. · The University of Texas Health Science Center, Houston

Trials 1

today NCT04887311 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04887311 Jul 2021 → Jun 2022 ataxia telangiectasia Matrix Biomed, Inc. Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MBM-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887311 ↗
Known as 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl “The active compound in MBM-01 (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) may substitute for the loss of ATM” NCT04887311 ↗
Action Restore “may substitute for the loss of ATM” NCT04887311 ↗
Route Oral “administered orally QD” NCT04887311 ↗